MacroGenics IncNASDAQ:MGNX
- LAST PRICE4.0700
- TODAY'S CHANGE (%)0.7600 (22.9607%)
- Bid / Lots4.0700/ 10
- Ask / Lots4.0900/ 6
- Open / Previous Close3.5100 / 3.3100
- Day Range
- 52 Week Range
- Volume9,777,152
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MGNX |
|---|---|---|
| 09:32 ET | 305079 | 3.4436 |
| 09:34 ET | 111197 | 3.5788 |
| 09:36 ET | 227631 | 3.7118 |
| 09:38 ET | 262256 | 3.7592 |
| 09:39 ET | 304364 | 3.79 |
| 09:41 ET | 356307 | 3.8699 |
| 09:43 ET | 404924 | 3.97 |
| 09:45 ET | 395150 | 4.1 |
| 09:48 ET | 368465 | 3.985 |
| 09:50 ET | 224937 | 3.9899 |
| 09:52 ET | 239189 | 3.825 |
| 09:54 ET | 170259 | 3.71 |
| 09:56 ET | 403396 | 3.48 |
| 09:57 ET | 233986 | 3.675 |
| 09:59 ET | 242002 | 3.77 |
| 10:01 ET | 152779 | 3.7301 |
| 10:03 ET | 133731 | 3.69 |
| 10:06 ET | 48618 | 3.69 |
| 10:08 ET | 142530 | 3.64 |
| 10:10 ET | 48085 | 3.6685 |
| 10:12 ET | 135848 | 3.72 |
| 10:14 ET | 40489 | 3.75 |
| 10:15 ET | 88260 | 3.73 |
| 10:17 ET | 68220 | 3.8 |
| 10:19 ET | 69109 | 3.78 |
| 10:21 ET | 33432 | 3.785 |
| 10:24 ET | 79169 | 3.8589 |
| 10:26 ET | 62834 | 3.87 |
| 10:28 ET | 90079 | 3.8012 |
| 10:30 ET | 53504 | 3.8001 |
| 10:32 ET | 103396 | 3.855 |
| 10:33 ET | 48166 | 3.84 |
| 10:35 ET | 98863 | 3.89 |
| 10:37 ET | 148179 | 3.96 |
| 10:39 ET | 44023 | 3.935 |
| 10:42 ET | 72867 | 3.95 |
| 10:44 ET | 205776 | 3.9923 |
| 10:46 ET | 192995 | 4.055 |
| 10:48 ET | 127442 | 4 |
| 10:50 ET | 86959 | 4.03 |
| 10:51 ET | 164689 | 4.1112 |
| 10:53 ET | 125634 | 4.065 |
| 10:55 ET | 154010 | 3.9912 |
| 10:57 ET | 57370 | 4.0211 |
| 11:00 ET | 101795 | 3.9812 |
| 11:02 ET | 98571 | 3.985 |
| 11:04 ET | 179637 | 3.9103 |
| 11:06 ET | 110041 | 3.905 |
| 11:08 ET | 113516 | 3.955 |
| 11:09 ET | 44316 | 3.985 |
| 11:11 ET | 72203 | 3.99 |
| 11:13 ET | 85821 | 3.95 |
| 11:15 ET | 21176 | 3.97 |
| 11:18 ET | 83255 | 4.005 |
| 11:20 ET | 38329 | 4.005 |
| 11:22 ET | 37331 | 3.995 |
| 11:24 ET | 30267 | 3.99 |
| 11:26 ET | 104709 | 3.96 |
| 11:27 ET | 75392 | 3.995 |
| 11:29 ET | 35627 | 3.9903 |
| 11:31 ET | 28351 | 3.99 |
| 11:33 ET | 162338 | 4.1107 |
| 11:36 ET | 89855 | 4.0215 |
| 11:38 ET | 16629 | 4.07 |
Today
MacroGenics, Inc. (MGNX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings, from 48 minutes ago by Dow Jones
48 minutes ago by Dow JonesMacroGenics to Participate in Upcoming Investor Conferences, from 4 hours ago by Dow Jones
4 hours ago by Dow JonesMacroGenics to Participate in Upcoming Investor Conferences, from 4 hours ago by Dow Jones
4 hours ago by Dow Jones
Yesterday
May 10, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
MacroGenics Inc | 207.1M | -10.8x | --- |
Innate Pharma SA | 196.8M | -25.0x | --- |
AVITA Medical Inc | 213.1M | -6.2x | --- |
Poseida Therapeutics Inc | 256.4M | -2.0x | --- |
Adaptimmune Therapeutics PLC | 286.2M | -2.2x | --- |
Genfit SA | 186.2M | -6.0x | --- |
Company Information
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.
Contact Information
- Headquarters
- 9704 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 301-251-5172
- Fax
- 301-251-5321
Executives
- Independent Chairman of the Board
- William Heiden
- President, Chief Executive Officer, Director
- Scott Koenig
- Chief Financial Officer, Senior Vice President, Corporate Secretary
- James Karrels
- Chief Operating Officer
- Eric Risser
- Senior Vice President - Research, Chief Scientific Officer
- Ezio Bonvini
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.1M |
|---|---|
Revenue (TTM) | $43.4M |
Shares Outstanding | 62.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.05 |
EPS | $-0.38 |
Book Value | $2.46 |
P/E Ratio | -10.8x |
Price/Sales (TTM) | 4.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -75.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
